Skip to main content
. 2023 Mar 8;72(7):2299–2308. doi: 10.1007/s00262-023-03417-3

Fig. 2.

Fig. 2

Progression-free survival and overall survival by age group. Kaplan–Meier estimates according to age (< 65 years and ≥ 65 years) for patients treated with ICI for a progression-free survival and b overall survival. Kaplan–Meier estimates according to age (65–69 years and ≥ 70 years) for elderly patients treated with ICI for c progression-free survival and d overall survival. ICI, immune checkpoint inhibitor; CI, confidence interval